-
Biocept Inks Research Pact With Protean BioDiagnostics For Target Selector Kit Advantages In Lung Cancer
Tuesday, February 23, 2021 - 12:35pm | 211Read More...Biocept Inc (NASDAQ: BIOC) will collaborate with Protean BioDiagnostics Inc to research Biocept's Target Selector molecular assay's ability to determine EGFR status in non-small cell lung cancer (NSCLC) patients. The research will be conducted in an independent...
-
G1 Therapeutics' Trilaciclib Wins FDA Nod For Mitigating Chemo Effects In Lung Cancer Patients
Tuesday, February 16, 2021 - 4:37am | 180Read More...G1 Therapeutics Inc (NASDAQ: GTHX) shares gain premarket after FDA approves COSELA (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression (damage to bone marrow) in adult patients when administered before a platinum/etoposide-containing...
-
AstraZeneca Lung Cancer Drug Gets EU Approval
Tuesday, September 1, 2020 - 3:41am | 320Read More...AstraZeneca Plc’s (NYSE: AZN) developmental drug – Imfinizi, has been approved by the European Commission after the Phase 3 clinical trial yielded positive results. What Happened: Imfinizi is the first line of treatment for adults with extensive-stage small-cell lung cancer in choice...
-
Checkpoint Therapeutics CEO On Tapping Into A $25 Billion Cancer Treatment Market
Wednesday, May 20, 2020 - 7:33am | 1320Read More...The following article is sponsored by the clinical communications unit of investor relations firm Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Since...
-
Penny Stock Rips 260% Higher On Fast Track Designation For Experimental Lung Cancer Gene Therapy
Tuesday, January 21, 2020 - 11:40am | 307Read More...Shares of thinly-traded gene therapy company Genprex Inc (NASDAQ: GNPX) are soaring on more than 50 times their average volume Tuesday. What Happened Genprex, which uses a non-viral, proprietary platform to deliver tumor suppressor genes to cancer cells, said the FDA has granted Fast Track...
-
AstraZeneca's Triple Combo Lung Cancer Therapy Aces Late-Stage Trial
Monday, October 28, 2019 - 2:13pm | 468Read More...AstraZeneca plc (NYSE: AZN) shares were advancing Monday following a clinical readout from the company. What Happened The U.K.-based pharma giant said its Phase 3 POSEIDON trial produced positive results. The study is evaluating AstraZeneca's Imfinzi — an anti-PD-L1...
-
The Bull Thesis For Merck Is Evaporating
Monday, October 30, 2017 - 10:14am | 349Read More...The bullish case for Merck & Co., Inc. (NYSE: MRK) has been "derailed" after the company signaled to investors last week a longer-than-expected delay in a key lung cancer trial for its Keytruda therapy. Morgan Stanley's David Risinger downgrades Merck's stock rating from Overweight to Equal-...
-
Analyst Grows Cautious On Merck's Keytruda After Company Withdraws European Application
Monday, October 30, 2017 - 9:08am | 403Read More...Analysts at Barclays no longer hold a bullish view on Merck & Co., Inc. (NYSE: MRK) due to a now diminished potential for its biggest value driver, Keytruda. The firm's Geoff Meacham downgraded Merck's stock rating from Overweight to Equal Weight with a price target slashed from $72 to $62....
-
Analyst: Entrectinib's Potential Gives Ignyta's Stock 116% Upside
Wednesday, October 18, 2017 - 10:23am | 327Read More...Analysts at Ladenburg Thalmann turned incrementally bullish on Ignyta Inc (NASDAQ: RXDX) after the company's therapy for the treatment of rare lung cancer showed encouraging results in a preliminary clinical trial among patients with a defective cancer-causing gene that is found in around 2...
-
Mirati Therapeutics Sitravatinib Data, Explained
Friday, September 15, 2017 - 9:42am | 395Read More...Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are skyrocketing Friday in reaction to its announcement of positive preliminary data from two ongoing clinical trials of its non-small cell lung cancer, or NSCLC, candidate sitravatinib. The company said the data will be presented at the IASLC 2017...
-
The Next Steps For OncoCyte After Better-Than-Expected Data
Tuesday, May 23, 2017 - 12:55pm | 487Read More...Shares of OncoCyte Corp (NYSE: OCX) were highly volatile Monday and Tuesday in reaction to the company presenting positive lung cancer blood test data to the American Thoracic Society. Keay Nakae of Chardan maintains a Buy rating on OncoCyte's stock with a price target raised from $5.50 to $7.50,...
-
Today's Top Mover: HTG Molecular Soars 60%
Thursday, March 23, 2017 - 7:53am | 338Read More...Shares of HTG Molecular Diagnostics Inc (NASDAQ: HTGM) soared higher by more than 60 percent early Thursday morning after the molecular profiling company confirmed regulatory approval for its products in Europe. HTG Molecular announced that it has obtained CE marking in the European Union for its...
-
Which Pharma Players Dominate The Lung Cancer Space?
Wednesday, January 25, 2017 - 2:40pm | 946Read More...Lung and bronchus cancer is the leading cause of cancer deaths in the United States, according to the National Cancer Institute. Lung cancer is of two types, namely non-small cell lung cancer, or NSCLC and small cell lung cancer, or SCLC, with the former more prevalent than the latter. Estimates by...
-
Clovis Oncology Issues Update On Rociletinib, Will Meet With FDA On April 12
Friday, February 12, 2016 - 11:09am | 189Read More...Clovis Oncology Inc (NASDAQ: CLVS) announced on Friday that the U.S. Food and Drug Administration has scheduled a date of April 12, 2016 to discuss a New Drug Application for its rociletinib therapy. Rociletinib is an investigational therapy for the treatment of patients with mutant epidermal...
-
Here's Why Shares Of Onco Genex Pharma Are Plunging
Thursday, January 21, 2016 - 9:28am | 172Read More...Shares of OncoGenex Pharmaceuticals Inc (NASDAQ: OGXI), a nano-cap and clinical-stage biopharmaceutical company, were trading lower by nearly 25 percent at $0.580 early Thursday morning. OncoGenex Pharmaceuticals announced after Wednesday's market close that data from its Phase 2 Spruce trial which...
